Israel
· Delayed Price · Currency is ILS · Price in ILADna Group (T.R.) Statistics
Total Valuation
Dna Group (T.R.) has a market cap or net worth of ILS 107.15 million. The enterprise value is 39.82 million.
| Market Cap | 107.15M |
| Enterprise Value | 39.82M |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Dna Group (T.R.) has 123.16 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Shares Outstanding | 123.16M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 52.38% |
| Owned by Institutions (%) | 0.14% |
| Float | 58.65M |
Valuation Ratios
The trailing PE ratio is 7.19.
| PE Ratio | 7.19 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.09 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.65 |
| EV / Sales | 130.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 101.37
| Current Ratio | 101.37 |
| Quick Ratio | 101.37 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 16.62% and return on invested capital (ROIC) is -1.37%.
| Return on Equity (ROE) | 16.62% |
| Return on Assets (ROA) | -1.35% |
| Return on Capital (ROIC) | -1.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.42% in the last 52 weeks. The beta is 0.10, so Dna Group (T.R.)'s price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +8.42% |
| 50-Day Moving Average | 73.56 |
| 200-Day Moving Average | 73.90 |
| Relative Strength Index (RSI) | 59.19 |
| Average Volume (20 Days) | 137,777 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dna Group (T.R.) had revenue of ILS 306,000 and earned 15.05 million in profits. Earnings per share was 0.12.
| Revenue | 306,000 |
| Gross Profit | 306,000 |
| Operating Income | -1.98M |
| Pretax Income | 15.25M |
| Net Income | 15.05M |
| EBITDA | n/a |
| EBIT | -1.98M |
| Earnings Per Share (EPS) | 0.12 |
Balance Sheet
| Cash & Cash Equivalents | 67.33M |
| Total Debt | n/a |
| Net Cash | 67.33M |
| Net Cash Per Share | 0.55 |
| Equity (Book Value) | 98.30M |
| Book Value Per Share | 0.80 |
| Working Capital | 66.85M |
Cash Flow
| Operating Cash Flow | 284,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -647.71% and 4,918.63%.
| Gross Margin | 100.00% |
| Operating Margin | -647.71% |
| Pretax Margin | 4,982.68% |
| Profit Margin | 4,918.63% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Dna Group (T.R.) does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | -0.02% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 10, 2019. It was a reverse split with a ratio of 0.1666666667.
| Last Split Date | Nov 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.1666666667 |
Scores
Dna Group (T.R.) has an Altman Z-Score of 42.67.
| Altman Z-Score | 42.67 |
| Piotroski F-Score | n/a |